Varex Imaging’s Strategic Merger with Teledyne Technologies

Varex Imaging Corporation (NASDAQ: VREX) has announced a definitive merger agreement with Teledyne Technologies and its subsidiary, a deal that will see Varex become a wholly‑owned subsidiary of Teledyne. The transaction, which is expected to close in early 2027, is subject to regulatory approvals and shareholder consent. A virtual special meeting is scheduled for October 28 2026, during which shareholders will vote on the merger and related matters.

Market Context

During the most recent 24‑hour trading period ending 8:22 PM Central Europe on Thursday, the Varex stock traded up 0.11 %. At the close, one share was valued at approximately USD 18.42, with a market capitalization of USD 775.5 million and a total trading volume of about USD 8.6 million. The company’s 200‑day simple moving average sits at USD 13.42, while its 52‑week high of USD 18.63 was recorded on 8 November 2026, and the 52‑week low of USD 9.09 was reached on 8 May 2026. Since the close of last month, the share price has slipped 0.32 %.

The company currently has 42.1 million shares outstanding. In the last 24 hours, its trading activity has been modest, with an overall volume of USD 8.6 million.

Merger Details and Shareholder Concerns

The merger agreement specifies a consolidation of the two entities, with Teledyne acquiring Varex and the latter becoming a wholly‑owned subsidiary. The definitive proxy statement, filed with the SEC, outlines the terms and conditions of the transaction. However, two shareholders have lodged complaints alleging deficiencies and misleading statements in the proxy. Varex has responded with supplemental disclosures aimed at clarifying the issues and has denied any material omissions.

Regulatory clearance remains a critical hurdle. The company must obtain antitrust and security approvals under the Hart‑Scott‑Roos (HSR) Act and the UK National Security and Investment Act. Both waiting periods are set to expire in late November 2026, potentially delaying the completion of the merger. Despite these uncertainties, Varex continues to recommend a vote in favour of the merger while monitoring ongoing litigation and regulatory review.

Comparative Market Performance

For context, other healthcare and industrial stocks have shown varied performance in the same 24‑hour window:

  • Employers (EIG): Flat 0 % change, trading at USD 53.08, with a market cap of USD 928.6 million and a P/E ratio of 142.93.
  • Hologic (HOLX.MX): Flat 0 % change, trading at MXN 1,260, with a market cap of MXN 17 billion and a P/E ratio of 31.55.
  • Hanmi (HAFC): Up 0.1 %, trading at USD 32.26, market cap USD 925.8 million, P/E 10.59.
  • Compass Minerals International (CMP): Down 0.68 %, trading at USD 21.35, market cap USD 917.3 million, P/E 52.27. The company reported a mixed earnings outlook, citing steady but modest revenue growth and a focus on infrastructure investment. Analysts remain neutral, anticipating steady performance amid commodity volatility.
  • Si‑Bone (SIBN): Up 1.36 %, trading at USD 21.55, market cap USD 920.6 million.

Company Overview

Varex Imaging Corporation, headquartered in Salt Lake City, Utah, specializes in the design, manufacture, and sale of X‑ray imaging components. Its product portfolio includes X‑ray tubes, flat‑panel detectors, imaging software, voltage connectors, and energy inspection accelerators. These components serve a broad spectrum of medical imaging applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, and computer‑aided detection. More information can be found on the company’s website at www.vareximaging.com .

This article provides a detailed overview of Varex Imaging’s merger announcement, current market activity, and related shareholder considerations, framed within the broader context of industry peers and regulatory dynamics.